| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
UM-164, a dasatinib analogue, is a potent and dual inhibitor of the Src/p38 kinase with potential anticancer activity for Triple-Negative Breast Cancer (TNBC). It is a promising lead compound for developing the first targeted therapeutic strategy against TNBC. c-Src has been shown to play a pivotal role in breast cancer progression, metastasis, and angiogenesis. In the clinic, however, the limited efficacy and high toxicity of existing c-Src inhibitors have tempered the enthusiasm for targeting c-Src. UM-164 binds the inactive kinase conformation of c-Src. Kinome-wide profiling of UM-164 identified that Src and p38 kinase families were potently inhibited by UM-164. UM-164 alters the cell localization of c-Src in TNBC cells. In xenograft models of TNBC, UM-164 resulted in a significant decrease of tumor growth compared with controls, with limited in vivo toxicity.
| ln Vitro |
UM-164 has demonstrated remarkable potency as a c-Src inhibitor in biochemical studies, with a binding constant that is similar to that of dasatinib (UM-164 Kd=2.7 nM, Dasatinib Kd=0.7 nM). In order to verify UM-164's ability to prevent c-Src from activating in vitro, the impact of UM-164 on c-Src autophosphorylation is investigated in two TNBC cell lines (MDA-MB 231 and SUM 149). It is shown that the inhibition of c-Src autophosphorylation is concentration- and time-dependent. Complete c-Src autophosphorylation abrogation is seen at 50 nM after 120 minutes, indicating that UM-164 is a strong c-Src inhibitor in vitro. UM-164 treatment of MDA-MB 231 and SUM 149 resulted in a 25% and 28% rise in the proportion of G0-G1 cells, respectively, and a 16% and 19% decrease in the fraction of S cells, according to flow cytometry experiments[1].
|
||
|---|---|---|---|
| ln Vivo |
MDA-MB 231 and SUM 149 cell lines are implanted into NCr/nude mice for the purpose of performing xenograft studies. The mice are randomized into control and treatment groups as soon as the tumors are evident. Every other day, five mice from each group receive an intraperitoneal injection of either a medication (10 and 20 mg/kg in both xenograft experiments; a 15 mg/kg dose is added to the SUM 149 xenograft trials) or a vehicle. Even after 52 days of therapy, the treated animals show no appreciable weight loss or obvious abnormalities at the chosen dosages of UM-164. On the other hand, compared to the vehicle-treated group, tumor development is considerably suppressed in both the 10 mg/kg and 20 mg/kg treatment groups (P<0.026 and P<0.004, respectively)[1].
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C30H31F3N8O3S
|
|
|---|---|---|
| Molecular Weight |
640.69
|
|
| Exact Mass |
640.22
|
|
| Elemental Analysis |
C, 56.24; H, 4.88; F, 8.90; N, 17.49; O, 7.49; S, 5.00
|
|
| CAS # |
903564-48-7
|
|
| Related CAS # |
|
|
| PubChem CID |
11714353
|
|
| Appearance |
White to off-white solid powder
|
|
| LogP |
4.7
|
|
| Hydrogen Bond Donor Count |
4
|
|
| Hydrogen Bond Acceptor Count |
13
|
|
| Rotatable Bond Count |
9
|
|
| Heavy Atom Count |
45
|
|
| Complexity |
991
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
ANEBQUSWQAQFQB-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C30H31F3N8O3S/c1-18-6-7-22(37-27(43)20-4-3-5-21(14-20)30(31,32)33)15-23(18)38-28(44)24-17-34-29(45-24)39-25-16-26(36-19(2)35-25)41-10-8-40(9-11-41)12-13-42/h3-7,14-17,42H,8-13H2,1-2H3,(H,37,43)(H,38,44)(H,34,35,36,39)
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.03.00
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (7.80 mM) in 50% PEG300 +50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5608 mL | 7.8041 mL | 15.6082 mL | |
| 5 mM | 0.3122 mL | 1.5608 mL | 3.1216 mL | |
| 10 mM | 0.1561 mL | 0.7804 mL | 1.5608 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Chemical structures of dasatinib and UM-164.A,UM-164 is a dasatinib analogue with an appended trifluoromethyl amide group (colored red) that causes binding to the inactive conformation of c-Src.BandC,MDA-MB 231 and SUM 149 cells were treated with UM-164 for 15, 30, 60, and 120 minutes at the indicated concentrations, and the whole-cell lysate was probed for P-Src/Tyr-419.Clin Cancer Res.2016 Oct 15;22(20):5087-5096. |
Inhibition of multiple signaling pathways by UM-164 and dasatinib in TNBC cell lines. Cells were treated with an increasing concentration of either UM-164 or dasatinib for 1 hour. Whole-cell lysates were collected and analyzed for the phospho-specific antibody of the indicated proteins, followed by immunoblotting for the corresponding total protein.A,SUM 149.B,MDA-MB 231.C,VARI-068, a TNBC cell line grown from a PDX.Clin Cancer Res.2016 Oct 15;22(20):5087-5096. |
Altered localization of c-Src when bound by UM-164. Representative fluorescence microscopy images of MDA-MB 468 cells treated with vehicle (DMSO), 5 μmol/L dasatinib, or 5 μmol/L UM-164 for 4 hours. In the vehicle-treated cells, c-Src (green) is predominately localized to the cell membranes. UM-164–treated cells show cytoplasmic punctate structures indicated by the white triangles. Nuclei are stained in blue (DAPI). Scale bar, 20 μm.Clin Cancer Res.2016 Oct 15;22(20):5087-5096. |
UM-164 treatment inhibits cell motility and invasion through c-Src–mediated FAK activation.Clin Cancer Res.2016 Oct 15;22(20):5087-5096. |
MDA-MB 231 and SUM 149 xenograft models.Clin Cancer Res.2016 Oct 15;22(20):5087-5096. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
